The aim was to capture interdisciplinary expertise from a large group of clinicians, reflecting
practice from across the UK and further, to inform subsequent development of a national …

Background Migraine occurs in around 15% of adults and is ranked as the seventh most
disabling disease amongst all diseases globally. Despite the available treatments many …

Background Calcitonin gene-related peptide plays an important role in migraine
pathophysiology. We evaluated eptinezumab, an intravenous (IV) anti-calcitonin gene …

Background OnabotulinumtoxinA is approved for the prevention of headache in those with
chronic migraine (CM); however, more clinical data on the risk-benefit profile for treatment …

Migräne ist mit einer Punktprävalenz von 20% bei Frauen und 8% bei Männern eine häufige
Erkrankung. Daher sind Leitlinien für die Behandlung von Migräneattacken sowie die …

OnabotulinumtoxinA is being increasingly used in the management of chronic migraine
(CM). Treatment with onabotulinumtoxinA poses challenges compared with traditional …

Botulinum neurotoxin (BoNT), derived from Clostridium botulinum, has been used
therapeutically for focal dystonia, spasticity, and chronic migraine. Its spectrum as a potential …

Objective The approved use of onabotulinumtoxinA for prophylaxis of headaches in patients
with chronic migraine (CM) involves treatment every 12 weeks. It is currently unknown …

Background. Migraine is one of the most common types of headache, and it is the second
most common cause of neurological disorders, with an annual prevalence of about 15% of …

Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine
and Headache Society and the German Page 1 Scientific Notes Treatment of migraine attacks …